Adebrelimab after chemoradiation for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called Adebrelimab as a maintenance therapy after you finish chemotherapy and radiation (given in smaller, more frequent doses) for limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer (cancer only in one lung and nearby lymph nodes).
- You have had 2 or fewer cycles of chemotherapy before, or no chemotherapy at all.
- You are able to take care of yourself and are up and about (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within a certain healthy range.
- You do not have a serious autoimmune disease, heart problems, or active infections like tuberculosis or hepatitis.
- You agree to use reliable birth control during the study and for 6 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a maintenance drug called Adebrelimab after initial chemo with or without radiation for limited-stage small cell lung cancer. It aims to see if continuing the drug helps keep the cancer from coming back.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
This study tests an immunotherapy (PD-L1 inhibitor) for people with limited-stage small cell lung cancer whose cancer stayed stable after chemo and radiation but still has MRD (small traces of cancer in the blood). The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Hear when a new Small Cell Lung Cancer, Limited Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.